Newsletter | November 3, 2022

11.03.22 -- Optimizing Your CNS Clinical Trial

Unlocking The Potential Of Plasma Biomarkers In CNS Trials For Alzheimer's Disease

Alzheimer’s disease, the most common form of dementia, is growing at a rapid pace. Discover why, in recent years, scientists have been exploring the use of plasma biomarkers as a noninvasive and cost-effective diagnostic tool for Alzheimer's disease.

Overcoming Stigma In Alzheimer's Disease

Health disparities among different racial groups impacted by Alzheimer’s disease add complexity to researching this disease. Explore how to address biases that thwart diversity and inclusion in dementia clinical research in this blog.

Mitigating Risk In ALS Clinical Development

The lack of available treatments for ALS has led many ALS patients to view clinical research as the best available care option, which can make it easier for sponsors to attract patients to their trials. Discover why thoughtful up-front planning and a clear understanding of the obstacles patients face are crucial when understanding the components of an ALS trial.

A New Dawn: At The Cusp Of The CNS Decade

This white paper explores the enablers of R&D breakthroughs in the treatment of neurological conditions, examines trends in how the pharmaceutical industry is embracing this momentous opportunity, and identifies critical success factors for central nervous system (CNS) innovators.

Central Nervous System Drug Development

Our expert central nervous system (CNS) teams have extensive experience and strong knowledge of the challenges expected when implementing and mitigating CNS clinical trials.

Request Information